Ximelagatran is a prodrug of melagatran, functioning as a direct thrombin inhibitor developed to improve oral bioavailability for anticoagulation therapy. As a potent anticoagulant, it was designed for… Read more

![Chemical structure of 1-[(2R)-N'-Boc-2-amino-2-cyclohexylacetyl]-N-(4'-cyanobenzyl)-2-L-azetidinecarboxamide-d11](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1356352-32-3-1-2R-N-Boc-2-amino-2-cyclohexylacetyl-N-4-cyanobenzyl-2-L-azetidinecarboxamide-d11.png&w=3840&q=75)


Ximelagatran is a prodrug of melagatran, functioning as a direct thrombin inhibitor developed to improve oral bioavailability for anticoagulation therapy. As a potent anticoagulant, it was designed for conditions such as the treatment of deep venous thrombosis, the prevention of secondary venous thromboembolism, and the reduction of stroke risk associated with atrial fibrillation. This category contains essential pharmaceutical reference standards, including the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, and relevant metabolites. Analytical laboratories utilize these high-purity materials to perform rigorous impurity profiling and ensure the accuracy of quantitative analysis. Furthermore, stable isotope labelled compounds are available to serve as reliable internal standards, facilitating precise method validation and quality control procedures during drug development and regulatory testing. These specialized chemical tools allow researchers to maintain strict compliance with quality standards throughout the analysis of this direct thrombin inhibitor.